Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Терапия ирбесартаном больных сахарным диабетом типа 2: метаболические эффекты и влияние на перфузию головного мозга
Терапия ирбесартаном больных сахарным диабетом типа 2: метаболические эффекты и влияние на перфузию головного мозга
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. World Health Organization. The world health report, 1997.
2. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403–18.
3. Stamler J. Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040–4.
4. Haffner S, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
5. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabet Care 1979; 2: 120–69.
6. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg. H-70 Study. Dement Geriatr Cegh Disord 2001; 12 (1): 33–10.
7. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabet Care 1995; 18 (2): 258–68.
8. Ford ES, Wayne H. Giles, William H. Dietz. Prevalence of the Metabolic Syndrome Among US Adults/Findings From the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9.
9. Vague J, Vague P, Tramoni M et al. Obesity and diabetes. Acta Diabetol Lat 1980; 17: 87–99.
10. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
11. Parving H-H, Lehnert H, Brochner-Mortensen et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med.
2. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403–18.
3. Stamler J. Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040–4.
4. Haffner S, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–34.
5. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabet Care 1979; 2: 120–69.
6. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg. H-70 Study. Dement Geriatr Cegh Disord 2001; 12 (1): 33–10.
7. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabet Care 1995; 18 (2): 258–68.
8. Ford ES, Wayne H. Giles, William H. Dietz. Prevalence of the Metabolic Syndrome Among US Adults/Findings From the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9.
9. Vague J, Vague P, Tramoni M et al. Obesity and diabetes. Acta Diabetol Lat 1980; 17: 87–99.
10. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
11. Parving H-H, Lehnert H, Brochner-Mortensen et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med.
Авторы
К.М.Мамырбаева, В.Б.Мычка, В.П.Масенко, В.Б.Сергиенко, И.Е.Чазова
НИИ кардиологии им. А.Л.Мясникова РКНПК Росздрава, Москва
НИИ кардиологии им. А.Л.Мясникова РКНПК Росздрава, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.